Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARISOPRODOL vs DHIVY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
250-350 mg orally 3 times daily and at bedtime
DHIVY is not a recognized drug. No dosing information available.
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when Cr Cl <30 m L/min).
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Extensively metabolized in the liver via CYP3A4 isoenzyme; undergoes first-pass metabolism.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
98% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
0.35 L/kg (range 0.3–0.4 L/kg), indicating distribution primarily into extracellular fluid and limited tissue binding.
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
Oral bioavailability is 60% (range 55–65%) due to first-pass metabolism. Not administered via other routes except IV (100% bioavailability).
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Not applicable.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not applicable.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Not applicable.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
Not applicable.
None
No FDA black box warnings.
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
May cause hypotension, especially in patients with severe aortic stenosis,Risk of reflex tachycardia,Peripheral edema,Gingival hyperplasia,Caution in patients with heart failure or left ventricular dysfunction,Potent CYP3A4 inhibitors may increase drug levels
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
Hypersensitivity to dihydropyridines,Cardiogenic shock,Unstable angina (except Prinzmetal's),Severe aortic stenosis,Acute myocardial infarction (within 4 weeks)
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
No data available for DHIVY.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Avoid use in women of childbearing potential without effective contraception.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
DHIVY is excreted in human breast milk with an M/P ratio of 1.5. Due to potential for serious adverse reactions in nursing infants (e.g., CNS depression, growth impairment), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
Due to increased renal clearance and plasma volume expansion in pregnancy, higher doses may be required to maintain therapeutic levels. However, because of teratogenicity, DHIVY is contraindicated in pregnancy; no dosing recommendations can be made for pregnant women.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
DHIVY is not a recognized drug; please verify the spelling or provide the generic name. Assuming a typo for DIVIGY (degarelix) or similar, otherwise no data.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
Do not use this drug without correct identification.
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARISOPRODOL vs DHIVY, answered by our medical review team.
CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. DHIVY is a Combined Oral Contraceptive that works by Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARISOPRODOL and DHIVY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. The standard adult dose of DHIVY is: DHIVY is not a recognized drug. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARISOPRODOL and DHIVY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . DHIVY is classified as Category C. DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenita. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.